FridayMay 13, 2022 12:02 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 Fiscal 2022 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced financial results for the third quarter ended March 31, 2022. “The third quarter of fiscal 2022 saw noticeable advancements across all of our programs, including commencing sales of the rare cannabinoids CBDV and CBT as raw ingredients for the health and wellness industry,” said Eric A. Adams, InMed president and CEO. “For the remainder of fiscal 2022, we will remain focused on driving our commercial operations by expanding our product portfolio, increasing sales of our existing and new rare…

Continue Reading

WednesdayMay 11, 2022 11:17 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright Global Investment Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the H.C. Wainwright Global Investment Hybrid Conference. The event is taking place May 23-26, 2022, at the Fontainebleau Miami Beach. Drysdale’s fireside chat will be webcast live at 12:30 p.m. ET on Wednesday, May 25. Interested parties should visit https://ibn.fm/0nlvQ to register and access the live webcast. An archived version of the webcast will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/hlEzH…

Continue Reading

WednesdayMay 11, 2022 11:10 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has closed the sale of non-core assets for $16.4 million. This news and additional information about the company was featured in an InvestmentPitch Media video, available for viewing on InvestmentPitch and YouTube or by visiting www.InvestmentPitch.com and entering “FSD Pharma” in the search box. Anthony Durkacz, interim CEO and co-executive chairman of FSD Pharma, said of the move: “This is a major accomplishment and puts us in a good position going forward especially considering the current state…

Continue Reading

TuesdayMay 10, 2022 2:09 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Closes CAD$16.4M Sale of Non-Core Assets

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the closing of the sale of the company’s former cannabis processing facility located in Cobourg, Ontario, Canada, for gross proceeds of CAD$16,400,000 in cash. “This is a major accomplishment and puts us in a good position going forward especially considering the current state of the capital markets. While most companies have taken huge write-downs on dispositions of cannabis-related assets, we were able to net significant profit from selling the facility,” said Anthony Durkacz, interim CEO…

Continue Reading

MondayMay 09, 2022 1:26 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from Phase I Clinical Trial for Novel Drug to Treat Concussion

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, has announced positive results from the first group of patients dosed with PRV-002 in its phase I clinical trial. According to the update, Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. Thus far, the drug has shown to be safe and well tolerated. “Based on our animal data and after reviewing our initial phase I trial safety reports, we are optimistic that PRV-002 will be a safe option for the treatment of concussion,” said Michael…

Continue Reading

ThursdayMay 05, 2022 3:01 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Demonstrating ‘Encouraging Promise in Treatment of GBM’

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical cancer drug developer, recently reported new advances in its rollout of a global clinical trial described as “potentially pivotal” in producing a treatment for an aggressive brain cancer, glioblastoma multiforme (“GBM”). On average, GBM is nearly 100% fatal just over a year into diagnosis. “CNS announced that France’s regulatory agencies have granted the company authority to pursue patient recruitment in the country…. France’s approval comes on the heels of similar authorization in Switzerland, where Swissmedic, the Swiss agency for therapeutic products, joined swissethics, the umbrella organization of the cantonal Ethics Committees (‘ECs’), in greenlighting…

Continue Reading

ThursdayMay 05, 2022 12:34 pm

BioMedNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Preclinical Study Findings to Be Showcased at Global Event Focused on Psychedelic-Assisted Therapy

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that an abstract highlighting preclinical data for its deuterated psilocybin analog CYB003 has been selected for a poster presentation at the “From Research to Reality” Global Summit on Psychedelic-Assisted Therapies and Medicines. The event is slated to take place from May 27-29, 2022, in Toronto, Canada. “It is an honor to participate in this inaugural conference devoted to psychedelic-assisted therapy and to be part of the rigorous scientific work being done in the field,” said Doug Drysdale, chief executive officer of Cybin. “The…

Continue Reading

ThursdayMay 05, 2022 11:44 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Participate in Groundbreaking Study with Trokie and Radicle Science

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced that its subsidiary, BayMedica, will be providing rare cannabinoids for use in Radicle Science Inc.’s Radicle Energy rare cannabinoid study to assess the effects of delta-9 (“d-9”) dominant tetrahydrocannabivarin (“THCV”) on energy, focus/attention, appetite and weight/BMI. According to the update, BayMedia will be supplying its highly pure d-9 dominant THCV, formulated into a proprietary lozenge manufactured by Trokie. “We are excited to be part of this groundbreaking study with Trokie and Radicle Science in advance of our commercial launch…

Continue Reading

WednesdayMay 04, 2022 3:14 pm

BioMedNewsBreaks – IBN’s BioMedWire to Raise Visibility of 2nd Annual Gene Therapy Patient Engagement Summit

IBN (“InvestorBrandNetwork”), an innovative content distributor and multifaceted communications organization with 50+ brands including BioMedWire (“BMW”), today announced that it will be collaborating with Hanson Wade as an official media sponsor for the upcoming 2nd Annual Gene Therapy Patient Engagement Summit. The event is slated to take place from June 7-9, 2022, in Boston, Massachusetts, and unite patient advocacy groups, engagement leaders and the patients themselves to provide insight and honest discussions. During the three-day summit, presentations will be held on a variety of topics, including managing expectations of gene therapy across stakeholders, incorporating the latest regulatory guidelines on patient…

Continue Reading

WednesdayMay 04, 2022 1:25 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Transition from Pure-Play Pharma R&D Firm Featured in Research Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. The piece details InMed Pharmaceuticals and its continued “transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness market. Product launches of high-value, rare cannabinoids into this market should provide the majority of its revenue in the near future,” the report reads. “INM also made notable advances in its pharmaceutical drug development programs, including its ongoing 755-201-EB Phase II…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050